Idiopathic Pulmonary Fibrosis

The Healio Editors compiled the most-read interstitial lung disease news published in 2021.

A nurse-led early palliative care intervention improved knowledge and disease preparedness among patients with idiopathic pulmonary fibrosis and their caregivers, researchers reported in the Annals of the American Thoracic Society.

Use of the Envisia Genomic Classifier impacted physician decision-making for evaluation of interstitial lung disease by increasing the number of correct idiopathic pulmonary fibrosis diagnoses that were made with high confidence.

The small airways may be a potential target to modify outcomes in patients with idiopathic pulmonary fibrosis, researchers reported in the American Journal of Respiratory and Critical Care Medicine.

In patients with acute exacerbation of idiopathic pulmonary fibrosis, adding IV cyclophosphamide to high-dose glucocorticoids increased mortality at 3 months, researchers reported at the European Respiratory Society International Congress.

In patients with idiopathic pulmonary fibrosis, multimorbidity was prevalent and comorbidity clusters may represent phenotypes with distinct profiles and characteristics, researchers reported in Respiratory Medicine.

This week, the FDA approves single-use bronchoscopes; a study finds the Moderna COVID-19 vaccine is safe and effective in adolescents; CMS nixes the most-favored nation pricing model for Medicare Part B; and more.

Adoption of pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis has been low in the U.S., according to an analysis published in the Annals of the American Thoracic Society.

In patients with idiopathic pulmonary fibrosis, antifibrotic treatment may reduce the risk for all-cause mortality and acute exacerbations, according to a systematic review and meta-analysis published in Chest.

This week, low-dose azithromycin did not improve cough in patients with IPF; tele-pulmonary rehab may lower barriers to care; the J&J vaccine protects against the delta variant; and more.